IL-17 receptor goes solo in autoimmune inflammation.

Humans Interleukin-17 Receptors, Interleukin-17 Antibodies, Blocking Autoimmune Diseases Inflammation

Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
12 09 2023
Historique:
received: 26 07 2023
revised: 13 08 2023
accepted: 14 08 2023
medline: 15 9 2023
pubmed: 14 9 2023
entrez: 13 9 2023
Statut: ppublish

Résumé

IL-17-blocking antibodies have shown little clinical effect in some autoimmune diseases such as multiple sclerosis. In this issue of Immunity, Luo et al. demonstrate that SHP2-Act1 complexes can mediate autonomous IL-17R signaling in the absence of the IL-17 ligand itself.

Identifiants

DOI: 10.1016/j.immuni.2023.08.007 PMID: 37703825
pubmed: 37703825
pii: S1074-7613(23)00363-1
doi: 10.1016/j.immuni.2023.08.007
pii:
doi:

Substances chimiques

Interleukin-17 0
Receptors, Interleukin-17 0
Antibodies, Blocking 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

1977-1980

Commentaires et corrections

Type : CommentOn

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Stefan Bittner (S)

Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn(2)), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Frauke Zipp (F)

Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn(2)), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. Electronic address: zipp@uni-mainz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › IL-17 receptor goes solo in autoimmune inflammation.
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-17 › IL-17 receptor goes solo in autoimmune inflammation.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux cytokines › Récepteurs aux interleukines › Récepteurs à l'interleukine-17 › IL-17 receptor goes solo in autoimmune inflammation.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps bloquants › IL-17 receptor goes solo in autoimmune inflammation.
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › IL-17 receptor goes solo in autoimmune inflammation.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › IL-17 receptor goes solo in autoimmune inflammation.